



29th March 2017

The Secretary
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

Clarification on news item appearing in www.reuters.com


Dear Sir/Madam

This is with reference to your letter no. L/SURV/ONL/RV/ZS/2016-17/301 dated 29th March 2017.

We would like to clarify that the new article titled "FDA approves Regeneron, Sanofi \$37,000 per year eczema drug" as mentioned in your letter is not relating to the operations of Sanofi India Limited. You would note that the news article appeared in US edition of Reuters and it is not relating to Sanofi business in India."

Thanking you,

Yours sincerely,
SANOFI INDIA LIMITED



GIRISH TEKCHANDANI
COMPANY SECRETARY



29th March 2017

The Secretary,
The National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex,
Bandra East,
Mumbai 400 050

Confirmation/Information on published news

Dear Sir/Madam

This is with reference to your letter no. NSE/CM/Surveillance/ 6714 dated 29th March 2017.

We would like to clarify that the new article titled "FDA approves Regeneron, Sanofi \$37,000 per year eczema drug" as mentioned in your letter is not relating to the operations of Sanofi India Limited. You would note that the news article appeared in US edition of Reuters and it is not relating to Sanofi business in India."

Thanking you,

Yours sincerely,
SANOFI INDIA LIMITED



GIRISH TEKCHANDANI
COMPANY SECRETARY